 |
12 Diseases |  |
138 Trials |
|
138 Trials |  |
3994 News |  |
| «12345678910111213...3940» |
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: Feasibility of Semaglutide in Advanced Lung Disease (clinicaltrials.gov) - Jan 31, 2024
P1/2, N=8, Recruiting, Sponsor: University of Pennsylvania
Not yet recruiting --> Recruiting
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial primary completion date: ESSENCE: Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Jan 29, 2024
P3, N=1200, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2028 --> Jun 2029
- ARTIFICIAL INTELLIGENCE ANALYSIS OF SOCIAL MEDIA POSTS ON GLUCAGON-LIKE-PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RA) (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_7573;
This study demonstrates the potential of AI to analyze social media data and generate insights on public perceptions of GLP-1RA. This may guide strategies for addressing barriers to GLP-1RA use and identification of new groups interested in using these medications to improve their health that may warrant further study.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Adempas (riociguat) / Bayer, Merck (MSD)
THE EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY ON DIURETIC RESISTANT FLUID RETENTION IN A PATIENT WITH PULMONARY HYPERTENSION AND RIGHT HEART FAILURE (Moderated Poster Theater 10) - Jan 26, 2024 - Abstract #ACC2024ACC_4825;
With uptitration of Remodulin to a dose of 38 ng/kg/min at his 5/1/23 office visit, JS continued to struggle with significant fluid retention despite a furosemide 80 mg twice a day and metolazone 2.5 mg weekly regimen... In obese patients with PAH, GLP-1 RAs can be an effective therapeutic agent to enhance flesh weight loss, resulting in dramatic reversal of diuretic resistant fluid retention in right heart failure.
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
EFFECT OF SEMAGLUTIDE ON CARDIORENAL OUTCOMES BY BASELINE BODY MASS INDEX AND PRIOR CARDIOVASCULAR DISEASE: POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6 (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_4499;
Cardiorenal effects of semaglutide vs placebo are consistent in people with T2D at high CV risk, regardless of baseline BMI or prior CVD. This analysis combines and confirms clinical trial evidence, supporting real-world use and efficacy of semaglutide in a broad population.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
EFFECTS OF 1 MG ONCE-WEEKLY SEMAGLUTIDE ON FUNCTIONAL CAPACITY IN PATIENTS WITH TYPE 2 DIABETES AND PERIPHERAL ARTERIAL DISEASE: TRIAL DESIGN AND BASELINE CHARACTERISTICS FROM STRIDE A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (Moderated Poster Theater 05) - Jan 26, 2024 - Abstract #ACC2024ACC_3960;
STRIDE enrolled patients with symptomatic PAD and T2D, frequent risk factors, and substantial functional impairment. These baseline characteristics highlight the comorbidities and disability associated with PAD and will enable assessment of the effects of semaglutide on functional capacity in patients with PAD and T2D.
- ||||||| LAI287/semaglutide (NN1535) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Awiqli (insulin icodec) / Novo Nordisk
Trial completion: A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) (clinicaltrials.gov) - Jan 25, 2024
P3, N=683, Completed, Sponsor: Novo Nordisk A/S
These baseline characteristics highlight the comorbidities and disability associated with PAD and will enable assessment of the effects of semaglutide on functional capacity in patients with PAD and T2D. Active, not recruiting --> Completed
- | Saxenda (liraglutide 3 mg) / Novo Nordisk
Journal, Surgery: Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and Recommendations for the Future. (Pubmed Central) - Jan 25, 2024
There is a paucity of literature available on the impact of these medications for plastic surgeons and their patients. As use becomes widespread, it is important for plastic surgeons to understand their indications, contraindications, appropriate perioperative management, and impact on plastic surgery procedures.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk, cagrilintide/semaglutide (CagriSema) / Novo Nordisk
New P3 trial: NN9388-4894: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (clinicaltrials.gov) - Jan 24, 2024
P3, N=1000, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Byetta (exenatide) / AstraZeneca
Review, Journal: The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review. (Pubmed Central) - Jan 22, 2024
Of all included studies, the quality of evidence was low, with short lengths of follow-up to identify durable effects of these medications on OSA outcomes and identify adverse events. More rigorous, RCTs with sufficient length of follow-up are required before consideration of formalising these medications into OSA treatment guidelines, frameworks and policies are warranted.
- ||| metformin / Generic mfg.
Retrospective data, Journal, Adverse events: Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN 6, and PIONEER 6. (Pubmed Central) - Jan 22, 2024
More rigorous, RCTs with sufficient length of follow-up are required before consideration of formalising these medications into OSA treatment guidelines, frameworks and policies are warranted. Concomitant metformin use does not increase occurrence of gastrointestinal symptoms during GLP-1RA initiation or impact GLP-1RA discontinuation.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Observational data, Retrospective data, Journal: Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study. (Pubmed Central) - Jan 19, 2024
In this study including obese subjects with poor glycemic control, switching dulaglutide to semaglutide showed more beneficial effects on both glycemic and weight control irrespective of age, body weight, and diabetes duration. Therefore, we should bear in mind that it would be better to start using a relatively new once-weekly GLP-1RA semaglutide in clinical practice, especially in obese subjects with poor glycemic control with other GLP-1RAs.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Januvia (sitagliptin) / Merck (MSD)
Journal: Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes. (Pubmed Central) - Jan 18, 2024
P3
Therefore, we should bear in mind that it would be better to start using a relatively new once-weekly GLP-1RA semaglutide in clinical practice, especially in obese subjects with poor glycemic control with other GLP-1RAs. This analysis confirms efficacy and safety of OW semaglutide (0.5 and 1.0 mg) in a Korean population with T2D.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes. (Pubmed Central) - Jan 17, 2024
Administration of a low-energy, high protein formula diet may ameliorate adverse nutritional effects of semaglutide in patients with T2D after LSG. (Ethics Committee of Toho University Sakura Medical Center approval number S18061).
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk, cagrilintide/semaglutide (CagriSema) / Novo Nordisk
New P1 trial: A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight (clinicaltrials.gov) - Jan 17, 2024
P1, N=180, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, pilocarpine / Generic mfg.
Journal: Semaglutide-associated hyposalivation: A report of case series. (Pubmed Central) - Jan 15, 2024
We are reporting for the first time hyposalivation associated with the use of semaglutide. Further prospective, larger studies are warranted to confirm these findings.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Natural Weight Loss or "Ozempic Face": Demystifying A Social Media Phenomenon. (Pubmed Central) - Jan 15, 2024
2024;23(1):1367-1368. doi:10.36849/JDD.7613.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal, HEOR: Treatment effect of semaglutide 2.4?mg on health-related quality of life from STEP 1 SF-6D derived from SF-36 with Australian weights. (Pubmed Central) - Jan 10, 2024
doi:10.36849/JDD.7613. To our knowledge, this is the first study showing statistically significant and clinically meaningful improvements in SF-6D utility scores with weight-loss pharmacotherapy in Australia.
- ||| Mounjaro (tirzepatide) / Eli Lilly
Journal, Adverse events: Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. (Pubmed Central) - Jan 9, 2024
To our knowledge, this is the first study showing statistically significant and clinically meaningful improvements in SF-6D utility scores with weight-loss pharmacotherapy in Australia. Superior weight reduction with tirzepatide versus comparators appears to be independent of reported N/V/D or GI AEs.
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Retrospective data, Review, Journal, HEOR, Real-world evidence, Cost-effectiveness, Cost effectiveness, Real-world: Glycemic Control, Weight Management, Cardiovascular Safety, and Cost-Effectiveness of Semaglutide for Patients with Type 2 Diabetes Mellitus: A Rapid Review and Meta-analysis of Real-World Studies. (Pubmed Central) - Jan 4, 2024
Superior weight reduction with tirzepatide versus comparators appears to be independent of reported N/V/D or GI AEs. This review consolidates the positive current evidence base for prescribing semaglutide to patients with T2DM, but further rigorous studies are still urgently required to develop practice guidelines as innovative drugs become commercially available.
- ||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus (clinicaltrials.gov) - Jan 3, 2024
P3, N=476, Completed, Sponsor: Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
This review consolidates the positive current evidence base for prescribing semaglutide to patients with T2DM, but further rigorous studies are still urgently required to develop practice guidelines as innovative drugs become commercially available. Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Oct 2023 | Trial primary completion date: Dec 2023 --> Jul 2023
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Trial completion date, Trial primary completion date: Triple Therapy in T1DM (clinicaltrials.gov) - Jan 3, 2024
P2/3, N=114, Recruiting, Sponsor: State University of New York at Buffalo
Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Oct 2023 | Trial primary completion date: Dec 2023 --> Jul 2023 Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion: A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight (clinicaltrials.gov) - Jan 1, 2024
P2, N=245, Completed, Sponsor: Novo Nordisk A/S
Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Active, not recruiting --> Completed
- || Firsocostat (GS-0976) / Gilead, cilofexor/firsocostat (GS-9674/GS-0976) / Gilead, cilofexor (GS-9674) / Gilead
Trial completion date, Trial primary completion date: Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Dec 31, 2023
P2, N=457, Active, not recruiting, Sponsor: Gilead Sciences
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion: TRANSITION-T2D: Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (clinicaltrials.gov) - Dec 28, 2023
P4, N=60, Completed, Sponsor: The Cleveland Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| mazdutide (LY3305677) / Eli Lilly
New P3 trial: DREAMS-3: A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity (clinicaltrials.gov) - Dec 27, 2023
P3, N=342, Not yet recruiting, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- | Mounjaro (tirzepatide) / Eli Lilly
Journal: Tirzepatide (Zepbound) for chronic weight management. (Pubmed Central) - Dec 26, 2023
Active, not recruiting --> Completed No abstract available
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date, Trial primary completion date: A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) (clinicaltrials.gov) - Dec 26, 2023
P3, N=568, Recruiting, Sponsor: Novo Nordisk A/S
No abstract available Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Nov 2024 --> May 2025
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Journal, HEOR, Cost-effectiveness, Cost effectiveness: The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults. (Pubmed Central) - Dec 25, 2023
This is the first short-term cost-effectiveness study of semaglutide and dulaglutide in T2DM Colombian patients. Our modeled results suggest that once-weekly semaglutide represents a cost-effective option for treating individuals with T2DM in Colombia who are not achieving glycaemia control with metformin, and it would be expected to improve HbA1C, promote greater weight loss and reduce costs from a third-payer perspective compared with treatment with dulaglutide.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Use of glucagon-like peptide-1 receptor agonists in eating disorder populations. (Pubmed Central) - Dec 23, 2023
It is possible that GLP-1As could maintain, worsen, or improve ED symptoms. This article reviews the limited literature on GLP-1As and ED symptoms, recommends future research, and provides clinicians with a guide for discussing GLP-1As with ED clients.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, zalfermin (NNC0194-0499) / Novo Nordisk
Trial completion date, Trial primary completion date: A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations (clinicaltrials.gov) - Dec 21, 2023
P1, N=48, Recruiting, Sponsor: Novo Nordisk A/S
This article reviews the limited literature on GLP-1As and ED symptoms, recommends future research, and provides clinicians with a guide for discussing GLP-1As with ED clients. Trial completion date: Nov 2023 --> Feb 2024 | Trial primary completion date: Nov 2023 --> Feb 2024
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, semaglutide/NNC0480-0389 (NN9389) / Novo Nordisk
CO-ADMINISTERED SEMAGLUTIDE AND GLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR AGONIST COMPARED WITH MONOTHERAPIES AND PLACEBO IN PEOPLE WITH TYPE 2 DIABETES: A RANDOMISED, DOSE-FINDING, PHASE 2 TRIAL (HALL I) - Dec 19, 2023 - Abstract #ATTD2024ATTD_305;
P2
Background and Aims: This phase 2 trial (NCT05144984) was designed to determine the dose ratio, efficacy and safety of a proposed fixed?dose combination of the glucagon?like peptide?1 analogue, semaglutide, and the glucose?dependent insulinotropic peptide receptor agonist (GIPRA), NNC0480?0389. This was a randomised, double?blind, placebo?controlled, dose?finding trial including adults with type 2 diabetes (HbA1c 7
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P2 trial: Semaglutide for Post-Smoking Cessation Weight Management (clinicaltrials.gov) - Dec 18, 2023
P2, N=197, Not yet recruiting, Sponsor: The University of Texas Health Science Center, Houston
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Retrospective data, Journal: Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN China. (Pubmed Central) - Dec 17, 2023
This was a randomised, double?blind, placebo?controlled, dose?finding trial including adults with type 2 diabetes (HbA1c 7 Treatment with OW SC semaglutide versus comparators was associated with increased proportions of participants with T2D meeting the composite metabolic endpoint.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Journal: Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study. (Pubmed Central) - Dec 17, 2023
Semaglutide added to empagliflozin did not change UACR, measured GFR, 24-hour systolic blood pressure, body weight or plasma renin levels in individuals with T2D and albuminuria. Semaglutide improved glycaemic control and plasma aldosterone levels compared to placebo.
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, zalfermin (NNC0194-0499) / Novo Nordisk
Enrollment closed: Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Dec 15, 2023
P2, N=672, Active, not recruiting, Sponsor: Novo Nordisk A/S
Semaglutide improved glycaemic control and plasma aldosterone levels compared to placebo. Recruiting --> Active, not recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, survodutide (BI 456906) / Zealand Pharma, Boehringer Ingelheim
Journal: Dose-response effects on HbA and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. (Pubmed Central) - Dec 14, 2023
P2
Survodutide reduced HbA levels and bodyweight after 16 weeks' treatment in participants with type 2 diabetes. Dose-related gastrointestinal AEs could be mitigated with slower dose escalations.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P3 trial: Efficacy of REducing cardiometabolic risk with SEmaglutide in Type 1 diabetes (EUDRACT) - Dec 8, 2023
P3, N=76, Not yet recruiting, Sponsor: Garvan Institute of Medical Research
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P3 trial: Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Dec 8, 2023
P3, N=588, Not yet recruiting, Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase (Pubmed Central) - Dec 7, 2023
Compared with DPP-4i, semaglutide was associated with lower follow-up HbA1c and BMI, greater reduction in HbA1c and BMI from baseline, and reduced likelihood of requiring treatment augmentation or insulin initiation to manage T2D in US adults, suggesting better durability of semaglutide vs DPP-4i. INFOGRAPHIC.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Enrollment open, Combination therapy: HALLMARK: The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients (clinicaltrials.gov) - Dec 6, 2023
P2, N=20, Recruiting, Sponsor: University Health Network, Toronto
INFOGRAPHIC. Not yet recruiting --> Recruiting
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk, cagrilintide/semaglutide (CagriSema) / Novo Nordisk
Enrollment open, Combination therapy: A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight (clinicaltrials.gov) - Dec 5, 2023
P3, N=800, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk, cagrilintide/semaglutide (CagriSema) / Novo Nordisk
Enrollment closed, Combination therapy: REDEFINE 2: A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight (clinicaltrials.gov) - Nov 28, 2023
P3, N=1200, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P1 trial: Subcutaneous Semaglutide in Systemic Scleroderma (clinicaltrials.gov) - Nov 28, 2023
P1, N=10, Not yet recruiting, Sponsor: Second Xiangya Hospital of Central South University
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open, Trial completion date: RESTORE: Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome (clinicaltrials.gov) - Nov 27, 2023
P3, N=80, Recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial completion date: Feb 2028 --> Jun 2028
- | efinopegdutide (HM12525A) / Merck (MSD)
Phase classification: A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) (clinicaltrials.gov) - Nov 27, 2023
P2, N=300, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting | Trial completion date: Feb 2028 --> Jun 2028 Phase classification: P2b --> P2
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. (Pubmed Central) - Nov 25, 2023
Social media platforms' users started promoting semaglutide/Ozempic as a weight-loss treatment, and the associated increase in demand has contributed to an ongoing worldwide shortage of the drug associated with levels of non-prescribed semaglutide intake...Establishing a clear cause-and-effect link between metabolic diseases, depression and medications is difficult because of their possible reciprocal relationship, shared underlying mechanisms and individual differences. Further research is needed to better understand the safety profile of these molecules and their putative impact on behavioral and non-behavioral addictions.
- | Journal: In brief: GI effects of GLP-1 receptor agonists. (Pubmed Central) - Nov 24, 2023
Further research is needed to better understand the safety profile of these molecules and their putative impact on behavioral and non-behavioral addictions. No abstract available
- The Effect of Semaglutide Treatment on Postoperative Outcomes of Total Hip Arthroplasty in Patients with Obesity: A Matched Study (OrthoLive, West Hall) - Nov 22, 2023 - Abstract #AAOS2024AAOS_4;
Semaglutide is a powerful anti-obesity medication recommended for select obese patients prior to undergoing THA. Postoperative complications after THA are similar between obese patients using Semaglutide compared to those who did not.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Observational data, Journal, Real-world evidence, Real-world: Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study. (Pubmed Central) - Nov 17, 2023
CKD severity barely influences treatment response. OW s.c. semaglutide can be useful to manage T2D patients with CKD in daily clinical practice.